euro-obesity-2016_posters-accepted-abstracts

16 / 16

Volume 6, Issue 8(Suppl) J Obes Weight Loss Ther 2016
ISSN: 2165-7904 JOWT, an open access journal
Page 61
Euro Obesity 2016
October 10-12, 2016
conferenceseries.com
7th Obesity & Endocrinology
Specialists Congress
October 10-12, 2016 Manchester, UK
Spatio-temporal gait during flat ground walking and obstacle crossing one year after bariatric surgery
Simone V Gill
Boston University, USA
Obesity negatively impacts motor function leading to an increase in fall risk. Massive weight loss improves some aspects of gait
on flat ground. However, we have little information about whether gait changes during flat ground walking and during more
complex motor tasks beyond flat ground walking (e.g., crossing obstacles). The purpose of this study was to examine how massive
weight loss after Roux-en-Y bariatric surgery influences gait during flat ground walking and obstacle crossing one year post bariatric
surgery. Nineteen adult females walked under 5conditions: Initial baseline walking on flat ground, crossing 3 obstacle heights and
final baseline walking on flat ground for a total of 25 trials. Spatio-temporal gait parameters were collected simultaneously using a
gait carpet and with body-worn sensors. Gait improved post-surgery with the strongest effect observed for double limb support time
during both flat ground walking (p<.001) and obstacle crossing (p<.001). The reduction in body mass index was correlated with
improved gait during both walking conditions (ps<.01). As expected, an increase in obstacle height altered gait (ps<.01). Improved
gait post-surgery was more pronounced during the highest obstacle condition (ps<.01). Massive weight loss results in improved
spatio-temporal gait patterns during flat ground walking. Practice during obstacle crossing may facilitate improved gait. Examining
how massive weight loss affects spatio-temporal gait may help create ways to minimize falls for adults with obesity and to encourage
a more active lifestyle.
J Obes Weight Loss Ther 2016, 6:8(Suppl)
How did an albino patient lose 148 lbs of weight? A case report
Zarnain Shah1, Samaneh A Motanagh2 and Syed Wajih Rizvi3
1Liaquat University of Medical & Health Sciences, Pakistan
2Ankara University, Turkey
3R-Endocrinology, USA
Introduction: Obesity is a highly prevalent and yet the most neglected disease. The number of overweight and obese people reached
2.3 billion and 700 million worldwide respectively, by the year 2015. Obesity is not a social disgrace but an actual disease with a major
genetic component to its etiology. Obesity treatment is a lifelong task. Weight reduction medications should be used as an adjunct
to diet restriction, exercise and behavioral modifications, when these measures alone have not resulted in adequate weight loss. We
hereby present a case of a morbidly obese male patient with oculocutaneous albinism who has lost 148 lbs of weight. Furthermore,
the report highlights the genetic link between oculocutaneous albinism and obesity.
Case Presentation: 28-year-old male with oculocutaneous albinism presented with 361.8 lbs of weight (BMI: 62.1) and complaint
of difficulty in losing weight. Physical examination revealed hypertension, low intelligence, gynecomastia and infantile testicles. Lab
investigations showed unregulated hyperlipidemia and hypotestosteronemia. The patient was prescribed Xenical (Orlistat) 120 mg.
Over the period of 5 years, he lost 83.8 lbs. After this time, Xenical’s effectiveness was significantly reduced. Consequently, the patient
was started on Victoza (Liraglutide) on which he lost 64 lbs in 3 years. Thus, a sum of 147.8 lbs of weight was lost without any side
effects of the drugs.
Discussion: Obesity needs to be treated within the healthcare system as any other complex disease. We observed Xenical and Victoza
to be safe and effective in reducing obesity. Substantial literature has emerged to show that in both Oculocutaneous albinism and
Prader-Willi syndrome (the most common genetic cause of obesity) the P gene is mutated on chromosome 15. This highlights the
genetic susceptibility of our albino patient for developing morbid obesity.
Conclusion: Obesity develops from the interplay of both genetic and environmental factors. This case clearly illustrates that Xenical
and Victoza can be safe and efficient for weight loss in a morbidly obese patient. Furthermore, scientific research in the genetic aspects
of obesity can help develop new strategies towards its prevention and treatment.